309 related articles for article (PubMed ID: 30409838)
1. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation.
Tian Y; Cai J; Gui W; Nichols RG; Koo I; Zhang J; Anitha M; Patterson AD
Drug Metab Dispos; 2019 Feb; 47(2):86-93. PubMed ID: 30409838
[TBL] [Abstract][Full Text] [Related]
2. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
[TBL] [Abstract][Full Text] [Related]
3. The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis.
Sun R; Kong B; Yang N; Cao B; Feng D; Yu X; Ge C; Feng S; Fei F; Huang J; Lu Z; Xie Y; Yang CS; Guo GL; Wang G; Aa J
Drug Metab Dispos; 2021 Mar; 49(3):276-286. PubMed ID: 33376148
[TBL] [Abstract][Full Text] [Related]
4. Berberine alters gut microbial function through modulation of bile acids.
Wolf PG; Devendran S; Doden HL; Ly LK; Moore T; Takei H; Nittono H; Murai T; Kurosawa T; Chlipala GE; Green SJ; Kakiyama G; Kashyap P; McCracken VJ; Gaskins HR; Gillevet PM; Ridlon JM
BMC Microbiol; 2021 Jan; 21(1):24. PubMed ID: 33430766
[TBL] [Abstract][Full Text] [Related]
5. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism.
Wang Y; Shou JW; Li XY; Zhao ZX; Fu J; He CY; Feng R; Ma C; Wen BY; Guo F; Yang XY; Han YX; Wang LL; Tong Q; You XF; Lin Y; Kong WJ; Si SY; Jiang JD
Metabolism; 2017 May; 70():72-84. PubMed ID: 28403947
[TBL] [Abstract][Full Text] [Related]
6. Berberine regulates fecal metabolites to ameliorate 5-fluorouracil induced intestinal mucositis through modulating gut microbiota.
Chen H; Zhang F; Li R; Liu Y; Wang X; Zhang X; Xu C; Li Y; Guo Y; Yao Q
Biomed Pharmacother; 2020 Apr; 124():109829. PubMed ID: 31958765
[TBL] [Abstract][Full Text] [Related]
7. Dose-response effect of berberine on bile acid profile and gut microbiota in mice.
Guo Y; Zhang Y; Huang W; Selwyn FP; Klaassen CD
BMC Complement Altern Med; 2016 Oct; 16(1):394. PubMed ID: 27756364
[TBL] [Abstract][Full Text] [Related]
8. An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice.
Xie C; Jiang C; Shi J; Gao X; Sun D; Sun L; Wang T; Takahashi S; Anitha M; Krausz KW; Patterson AD; Gonzalez FJ
Diabetes; 2017 Mar; 66(3):613-626. PubMed ID: 28223344
[TBL] [Abstract][Full Text] [Related]
9. A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis.
Chen H; Zhang F; Zhang J; Zhang X; Guo Y; Yao Q
Front Immunol; 2020; 11():588079. PubMed ID: 33072135
[TBL] [Abstract][Full Text] [Related]
10. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
11. Persistent Organic Pollutants Modify Gut Microbiota-Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation.
Zhang L; Nichols RG; Correll J; Murray IA; Tanaka N; Smith PB; Hubbard TD; Sebastian A; Albert I; Hatzakis E; Gonzalez FJ; Perdew GH; Patterson AD
Environ Health Perspect; 2015 Jul; 123(7):679-88. PubMed ID: 25768209
[TBL] [Abstract][Full Text] [Related]
12. Identification of a mouse Lactobacillus johnsonii strain with deconjugase activity against the FXR antagonist T-β-MCA.
DiMarzio M; Rusconi B; Yennawar NH; Eppinger M; Patterson AD; Dudley EG
PLoS One; 2017; 12(9):e0183564. PubMed ID: 28910295
[TBL] [Abstract][Full Text] [Related]
13. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity.
Li F; Jiang C; Krausz KW; Li Y; Albert I; Hao H; Fabre KM; Mitchell JB; Patterson AD; Gonzalez FJ
Nat Commun; 2013; 4():2384. PubMed ID: 24064762
[TBL] [Abstract][Full Text] [Related]
14. Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids.
Yao Y; Chen H; Yan L; Wang W; Wang D
Biomed Pharmacother; 2020 Nov; 131():110669. PubMed ID: 32937246
[TBL] [Abstract][Full Text] [Related]
15. Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice.
Li CN; Wang X; Lei L; Liu MZ; Li RC; Sun SJ; Liu SN; Huan Y; Zhou T; Liu Q; Cao H; Bai GL; Han YW; Shen ZF
Phytother Res; 2020 May; 34(5):1166-1174. PubMed ID: 31833107
[TBL] [Abstract][Full Text] [Related]
16. Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism.
Zhang L; Xie C; Nichols RG; Chan SH; Jiang C; Hao R; Smith PB; Cai J; Simons MN; Hatzakis E; Maranas CD; Gonzalez FJ; Patterson AD
mSystems; 2016; 1(5):. PubMed ID: 27822554
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress Intestinal Regulation of Bile Acid Synthesis.
Ovadia C; Perdones-Montero A; Spagou K; Smith A; Sarafian MH; Gomez-Romero M; Bellafante E; Clarke LCD; Sadiq F; Nikolova V; Mitchell A; Dixon PH; Santa-Pinter N; Wahlström A; Abu-Hayyeh S; Walters JRF; Marschall HU; Holmes E; Marchesi JR; Williamson C
Hepatology; 2019 Jul; 70(1):276-293. PubMed ID: 30983011
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
[TBL] [Abstract][Full Text] [Related]
19. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
[TBL] [Abstract][Full Text] [Related]
20. Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice.
Li M; Zhou W; Dang Y; Li C; Ji G; Zhang L
Biomed Pharmacother; 2020 Dec; 132():110953. PubMed ID: 33254441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
